Dipeptidyl Peptidase ‐4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study

ConclusionsPatients in the veteran population with T2DM treated with DPP‐4 inhibitors did not demonstrate a significant increase in risk for heart failure exacerbation, regardless of whether a patient had been previously diagnosed with heart failure. This finding potentially supports safe usage of DPP‐4 inhibitors in this patient population regardless of heart failure diagnosis.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 1, 2018 Category: Drugs & Pharmacology Authors: Michael R Cobretti, Benjamin Bowman, Ted Grabarczyk, Emily Potter Tags: Original Research Article Source Type: research